Comparative Efficacy and Safety of FLT3 Inhibitor–Based Frontline Regimens in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A Systematic Review and Network Meta-Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #AML-724; Location: LEVEL 3, HALL B3; "Introduction: The rapid expansion of FLT3 inhibitors (FLT3i) and venetoclax (VEN)-based combinations has transformed the frontline landscape for FLT3-mutated AML...Gilteritinib-based triplets achieved the highest complete response/ complete remission with incomplete count recovery (CR/Cri) rates (OR, 3.15; 95% CI, 2.10–4.72) and measurable residual disease negativity (OR, 2.80; 95% CI, 1.65–4.75) vs midostaurin + 7+3, although OS benefit was partially offset by early mortality. For hypomethylating agent backbones, VEN + FLT3i triplets outperformed VEN + AZA (azacitidine) doublets in event-free survival (HR, 0.68; 95% CI, 0.49–0.94)... While triplet therapies offer the deepest molecular responses, quizartinib-based intensive induction currently represents the most favorable balance of survival and safety for fit patients; notably, the overall risk of bias across included studies was low. 7+3: 7 days of cytarabine and an anthracycline for the first 3 days, ASH:..."
Retrospective data • Review • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3
|
|
Sadhu Aishwarya Reddy 1; Zoya Sohail 2; Deepti Botlaguduru 3; Rakhshanda Khan 4; Harshawardhan Dhanraj Ramteke 5; Dineshbaba Murugavel 6
|